Yeapuri, Pravin
Machhi, Jatin
Lu, Yaman
Abdelmoaty, Mai Mohamed
Kadry, Rana
Patel, Milankumar
Bhattarai, Shaurav
Lu, Eugene
Namminga, Krista L.
Olson, Katherine E.
Foster, Emma G.
Mosley, R. Lee
Gendelman, Howard E.
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (2R01 NS034239)
Article History
Received: 29 May 2023
Accepted: 4 December 2023
First Online: 18 December 2023
Declarations
:
: The study was reviewed and approved by the animal welfare review board of the University of Nebraska Medical Center.
: Not applicable.
: J.M., P.Y., R.L.M., and H.E.G. are named inventors on provisional patent entitled “Cell therapy for Alzheimer’s disease” which is based on the Aβ-TCR sequence (EFS ID: 42475225, Application number: 63175747, Docket number: 21084P). H.E.G is a member of the scientific advisory board at Longevity Biotech and a co-founder of Exavir Therapeutics, Inc. All other authors declare no conflict of interest.